Projekt
First time ultra-sensitive and simultaneous quantification of proteins, interactions, and post-translational modifications in single cells to enable exponential growth in proteomics and interactomics
In a human cell there are about 20k protein coding genes (genome) that originate ~100k proteins (proteome). Proteins are involved in complex networks of protein-protein interactions (PPIs) influenced by post-translational modifications (PTMs), the interactome of living cells (~800,000 entities). The genome is mostly s…
In a human cell there are about 20k protein coding genes (genome) that originate ~100k proteins (proteome). Proteins are involved in complex networks of protein-protein interactions (PPIs) influenced by post-translational modifications (PTMs), the interactome of living cells (~800,000 entities). The genome is mostly static throughout cell lifetime and can be sequenced today in <1h. The proteome and interactome are changing with e.g., environment and health, and not yet fully known. Today's methods for proteomics and interactomics are tedious, and lack sensitivity, quantitativity and parallelism.
PICO-NGS combines ultra-high sensitivity (>10 fM) with high parallelism measuring proteins, PPIs, and PTMs simultaneously (>50 targets). This will disrupt the global proteomics market (€29 B worth, 16% CAGR). This will fertilise ground-breaking academic research and accelerate developments in e.g., Pharma (drug discovery), Biotech (biomarkers/diagnosis), and Agrotech (crop sciences) industries.
Technologien
- Biotechnologie Biotechnologie – Überblick über Forschungsprojekte, Patente und Akteure im TechnologieAtlas.
Themengebiete
- Gesundheit Gesundheit – Überblick über Forschungsprojekte, Patente und Akteure im TechnologieAtlas.
Unternehmen
- ACTOME GMBH ACTOME GMBH – Unternehmen mit Aktivitäten in Forschung und Innovation.